1. P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS. (23rd June 2022) Authors: Ali, H.; Kishtagari, A.; Maher, K.; Mohan, S.; Mazumder, A.; Chamoun, K.; Karasik, I.; Sbar, E.; Dugom, L.; Tamir, S.; Wang, X.; Prchal, J.; Tantravahi, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 895 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗